Brainstorm Cell Therapeutics, Inc. is a biotechnology company, which develops and commercializes autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis, Progressive Multiple Sclerosis, Alzheimer's disease, and other neurodegenerative diseases. Its pipeline, NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and improve neurological function. The company was founded by Irit Arbel on September 22, 2000 and is headquartered in New York, NY.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
27
Frequently Asked Questions
What is Market Cap of Brainstorm Cell Therapeutics, Inc.?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Brainstorm Cell Therapeutics, Inc. market cap is $7.47M.
What is the 52-week high for Brainstorm Cell Therapeutics, Inc.?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Brainstorm Cell Therapeutics, Inc. 52 week high is $0.8936 as of October 04, 2025.
What is the 52-week low for Brainstorm Cell Therapeutics, Inc.?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Brainstorm Cell Therapeutics, Inc. 52 week low is $0.521 as of October 04, 2025.
What is Brainstorm Cell Therapeutics, Inc. stock price today?
Brainstorm Cell Therapeutics, Inc. stock price today is $0.7198.
What was Brainstorm Cell Therapeutics, Inc. stock price yesterday?
Brainstorm Cell Therapeutics, Inc. stock price yesterday was $0.72.
What is the PE ratio of Brainstorm Cell Therapeutics, Inc.?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Brainstorm Cell Therapeutics, Inc.’s P/E ratio is -0.40.
What is the Price-to-Book ratio of Brainstorm Cell Therapeutics, Inc.?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Brainstorm Cell Therapeutics, Inc. P/B ratio is -1.2026.
What is the 50-day moving average of Brainstorm Cell Therapeutics, Inc.?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Brainstorm Cell Therapeutics, Inc. 50-day moving average is $0.6878.
How many employess does Brainstorm Cell Therapeutics, Inc. has?
Brainstorm Cell Therapeutics, Inc. has 27 employees.